German Health Minister Jens Spahn. © obs/Deutsche Unternehmerbörse DUB.de GmbH/BMG

The German Health Ministry has requested €6.2bn from the Federal Ministry of Finance to purchase up to 635 million additional doses of COVID-19 vaccines.

© 3D Animations Company/Pixabay.com

V-Bio Ventures has announced the first closing of its V-Bio Fund 2 at €78m. The fund is focussed on investments into early stage life sciences companies in Belgium and the EU.
 
·      

The transatlantic Abingworth Bioventures 8 Fund has been closed at $464m to invest in US, UK and European life science companies.   

© NIAID

As rapidly spreading mutants of SARS-CoV-2 are emerging, two Tuebingen-based vaccine developers will develop multivalent COVID-19 vaccines.

Rentschler Biopharma's headquarters in Laupheim, Germany. © Rentschler Biopharma SE

German CDMO Rentschler Biopharma is expanding cCMP production of CureVac NV’s RNA-based COVID-19 vaccine candidate CVnCoV.

© pixabay.com

Enthera Pharmaceuticals extends its €28m Series A financing from last July to a total of €35m as Roche Venture Fund joins the company’s investor syndicate.

© NIAID

A US subsidiary of Hamburg-based Evotec SE has won a contract from the US government to produce antibodies against SARS-CoV-2.

Spanish Accure Therapeutics appoints Dr Rossella Medori as new Chief Medical officer.

Just last November, the start-up company secured US$8.5m in a round led by Tal Capital and Entrée Capital, with participation by the CBG Group, Xenia Ventures, VLX Ventures, and with the support of the Israel Innovation Authority. Photo: Courtesy © Omnix Medical

Israel’s Omnix Medical has been granted €10.8m needed to start Phase I/II development of a potential AMR breaking drug in Gram-negative bugs.

German Health Minister Jens Spahn. © Jens Spahn/BMG

Germany has become the first country in Europe to buy the US emergency-approved COVID-19 antibody therapies from Regeneron and Eli Lilly.